Porton Advanced宣布与Eureka Therapeutics合作以加速T细胞疗法的开发-动脉网

Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T‑Cell Therapy Development

CISION 等信源发布 2025-03-19 22:00



可切换为仅中文







CRANBURY, N.J.

新泽西州克兰伯里

，

March 19, 2025

2025年3月19日

/PRNewswire/ -- Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies. .

/PRNewswire/ -- 领先的合同开发和制造组织（CDMO），专注于先进治疗药物产品（ATMPs）的Porton Advanced欣然宣布与Eureka Therapeutics, Inc.达成合作。Eureka Therapeutics是一家临床阶段的生物技术公司，致力于开发针对实体瘤和血液系统恶性肿瘤的新型T细胞疗法。

继续阅读

Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T Cell Therapy Development

保兰先进公司宣布与优瑞卡治疗公司合作以加速T细胞疗法的开发

Eureka Therapeutics, headquartered in the

总部位于加利福尼亚州埃默里维尔的优睿科医疗公司

San Francisco Bay Area

旧金山湾区

, leverages its proprietary ARTEMIS

，利用其专有的 ARTEMIS 技术

cell receptor and E‑ALPHA

细胞受体和E-ALPHA

antibody discovery platforms to drive innovation in safer, more effective T‑cell therapies. Through this collaboration, the two parties aim to accelerate Eureka's global clinical development by capitalizing on Porton Advanced's world-class cell and gene therapy manufacturing capabilities at their GMP sites..

抗体发现平台，以推动更安全、更有效的T细胞疗法的创新。通过此次合作，双方旨在利用Porton Advanced在其GMP站点的世界一流的细胞和基因治疗生产能力，加速Eureka的全球临床开发进程。

Oliver Ju

奥利弗·朱

, Chairman of Porton Advanced, commented: 'We are delighted to establish our partnership with Eureka. The seamless completion of the initial part of our collaboration program underscores our team's operational excellence and commitment to quality. Our continued collaboration will leverage our flexible models and state‑of‑the‑art manufacturing capabilities to expedite the development of groundbreaking advanced therapies.'.

Porton Advanced董事长评论道：“我们很高兴与Eureka建立合作关系。我们合作计划的初始部分顺利完成，彰显了我们团队卓越的运营能力和对品质的承诺。我们持续的合作将利用我们灵活的模式和最先进的生产能力，加速开创性先进疗法的开发。”

Dr. Cheng Liu, Founder and CEO of Eureka Therapeutics, stated: 'We are confident that through close collaboration with Porton Advanced, Eureka is well-positioned to accelerate our key pipeline programs, supported by Porton's robust and reliable manufacturing capabilities.'

刘诚博士，优瑞科生物创始人兼首席执行官表示：“我们相信，通过与颇尔先进的紧密合作，优瑞科能够充分利用颇尔强大而可靠的生产能力，加速我们关键的管线项目。”

Accelerating Advanced Therapy Pipeline Development

加快先进治疗管线的开发

Following the successful technology establishment, Porton Advanced will continue to support Eureka's Investigator-Initiated Trials (IITs) by providing CAR-T manufacturing services that adhere to stringent quality standards. These studies, supported by Porton Advanced's end-to-end CDMO platform, are designed to generate critical data for subsequent clinical milestones to further advance Eureka's innovative T-cell therapies..

在成功建立技术后，Porton Advanced 将继续通过提供符合严格质量标准的 CAR-T 制造服务来支持 Eureka 的研究者发起的试验 (IITs)。这些研究得到了 Porton Advanced 端到端 CDMO 平台的支持，旨在为后续的临床里程碑生成关键数据，以进一步推动 Eureka 创新的 T 细胞疗法的发展。

Porton Advanced: Enabling Global Innovations in Advanced Therapies

普洛特先进：推动全球先进治疗创新

Porton Advanced's proven process development capabilities, GMP-compliant facilities (meeting US, EU, and

凯莱英先进的工艺开发能力，符合GMP标准的设施（符合美国、欧盟和

China

中国

standards), and extensive project experience position it as a strategic partner for international biotech companies seeking clinical and commercial CDMOs. This collaboration further validates Porton Advanced's unique value in facilitating global advanced therapy pipelines.

标准），以及广泛的项目经验，使其成为寻求临床和商业CDMO的国际生物技术公司的战略合作伙伴。此次合作进一步验证了Porton Advanced在促进全球先进治疗管道方面的独特价值。

Porton Advanced has an extensive track record, cumulatively supporting over 60 ATMP Clinical, IND, and IIT projects in

保诺科技拥有丰富的经验，累计支持了60多个ATMP临床、IND和IIT项目。

China

中国

, with orders exceeding 140 IIT batches and maintaining a flawless release success rate for all completed batches. This record highlights the company's consistent capability to meet high-quality manufacturing standards.

，订单超过140个IIT批次，并保持了所有已完成批次的完美放行成功率。这一记录突显了该公司持续满足高质量制造标准的能力。

Porton Advanced will use all the resources, experience, and skills at the company's disposal to ensure the success of Porton Advanced's collaboration with Eureka.

Porton Advanced将利用公司掌握的所有资源、经验和技能，确保Porton Advanced与Eureka的合作取得成功。

About Porton Advanced

关于博腾股份

Porton Advanced Solutions is a subsidiary of the leading CDMO, Porton Pharma Solutions. Porton Advanced has headquarters in

Porton Advanced Solutions是领先的CDMO公司Porton Pharma Solutions的子公司。Porton Advanced总部位于

Cranbury, New Jersey

新泽西州克兰伯里

, and two GMP sites in Suzhou,

，以及苏州的两个GMP工厂，

China

中国

, providing end-to-end CDMO solutions for ATMPs.

，为ATMP提供端到端的CDMO解决方案。

我们

offer services from cell banking, process, and analytical method development, cGMP production to fill & finish, covering different stages of drug development from early research, IITs, Investigational New Drug (IND) applications, clinical trials, New Drug Applications (NDA), to commercialization.

提供从细胞库、工艺、分析方法开发、cGMP生产到灌装和包装的服务，涵盖药物开发的不同阶段，包括早期研究、IIT、新药临床试验申请（IND）、临床试验、新药申请（NDA）到商业化。

Porton Advanced has developed specialized CRO and CDMO platforms focusing on plasmids, viral vectors (lentiviral vector, adenoviral vector, AAV,etc), cell therapy CMC services including CAR-T, TCR-T, CAR-NK, HSC, exosome, etc) and nucleic acid therapies. Our state-of-the-art, GMP-compliant facilities span an impressive 215,000 sq ft, equipped with 10 viral vector production lines, 12 GMP-compliant cell therapy production suites (including 2 suites for infectious donors), and a multitude of clean rooms.

博腾先进开发了专注于质粒、病毒载体（慢病毒载体、腺病毒载体、AAV等）、细胞治疗CMC服务（包括CAR-T、TCR-T、CAR-NK、HSC、外泌体等）以及核酸疗法的专业CRO和CDMO平台。我们拥有最先进的、符合GMP标准的设施，占地达215,000平方英尺，配备了10条病毒载体生产线、12个符合GMP标准的细胞治疗生产套间（包括2个用于感染供体的套间）以及众多洁净室。

As of now, we have successfully supported our clients to secure 16 global IND approvals from NMPA, FDA, and Medsafe, with 5 ongoing Phase I/II ATMP projects. Additionally, Porton Advanced has supported the successful transition of several overseas clinical-stage pipelines into .

截至目前，我们已经成功支持客户获得来自NMPA、FDA和Medsafe的16项全球IND批准，并有5个正在进行的I/II期ATMP项目。此外，Porton Advanced还成功支持了多个海外临床阶段管线的转移。

China

中国

。

Porton Advanced is committed to a customer-centric approach, providing excellent global, end-to-end CDMO services to our clients, enabling effective drugs to benefit the public sooner.

保诺科技致力于以客户为中心，为我们的客户提供优质的全球端到端CDMO服务，助力好药更早惠及大众。

For more information about Porton Advanced, please visit:

有关 Porton Advanced 的更多信息，请访问：

www.portonadvanced.com

。

Media Contact

媒体联系人

info@portonadvanced.com

SOURCE Porton Advanced Solutions

源代码：Porton Advanced Solutions

WANT YOUR COMPANY'S NEWS

想要你公司的新闻